Viatris And Biocon Line Up EU Bevacizumab
As Accord Receives Positive CHMP Opinion For Abiraterone
Executive Summary
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
You may also be interested in...
Viatris Eyes Gilenya Generic Following ‘Unreliable’ Study Data
Viatris has bounced back from withdrawing its application for a generic version of Gilenya in the EU with a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Biocon And Viatris Ready To Launch EU Bevacizumab
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
Krka’s Zytiga Rival Wins CHMP Nod
Krka’s generic version of Janssen’s Zytiga has garnered a positive opinion from the EMA’s CHMP, along with Pinax Pharma’s Celsunax ioflupane generic of DaTSCAN and Nova Laboratories’ hybrid Jayempi azathioprine oral suspension.